Total
0
Shares
WPD Pharmaceuticals (CSE:WBIO) applies for a management cease trade order
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • WPD Pharmaceuticals (WBIO) applies for a temporary management cease trade order
  • WPD is seeking the MCTO as it is unable to file its annual filings within the deadline as required under National Instrument 51-102
  • WPD anticipates that it will be in a position to file the annual filings on or about May 10, 2021
  • WPD is a biotechnology research and development company with a focus on oncology
  • WPD Pharmaceuticals Inc. (WBIO) is in the grey and is trading at C$0.29 at 12:47 pm ET

WPD Pharmaceuticals Inc. (WBIO) has applied to the British Columbia Securities Commission for a temporary management cease trade order.

If granted, the order will prohibit trading in securities of WPD Pharmaceuticals by certain insiders of the company, whether direct or indirect.

WPD is seeking the MCTO as it is unable to file its annual filings within the deadline as required under National Instrument 51-102.

WPD anticipates that it will be in a position to file the annual filings on or about May 10, 2021.

It also confirms that it will comply with the alternative information guidelines included in NP 12-203 so long as the Annual Filings are outstanding.

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules.

WPD has licensed in certain countries 10 novel drug candidates with 4 that are in the clinical development stage.

These drug candidates were researched at medical institutions, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD Pharmaceuticals Inc. (WBIO) is in the grey and is trading at C$0.29 at 12:47 pm ET.

More From The Market Herald
HempFusion (TSX:CBD.U) announces US$2M private placement

" HempFusion (TSX:CBD.U) increases private placement

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.